ÂÜÀòÂÒÂ×

Holger Koch has a diverse and extensive work experience spanning multiple companies and roles. In 2005, Holger Koch began their career at Kenta Biotech, initially as a Research Scientist, where they identified target structures for monoclonal antibodies and developed a diagnostic assay. Holger then became a Project Leader, leading a team in the successful initiation of a clinical trial for a monoclonal antibody. In 2012, they became the Head of Preclinical Research & Project Management, overseeing the monoclonal antibody development portfolio and implementing project management processes.

In 2013, Holger Koch joined Novartis Pharma Stein AG as the Product Steward Steriles PU Pre-filled Syringe, leading the launch process unit and contributing to regulatory inspections and dossier submissions.

In 2015, Holger Koch joined Takeda as the (Associate) Director Assay Development Lead Serology, responsible for the assay strategy of the Norovirus vaccine program. Holger later became the Senior Director, Global Head Clinical Serology & Assay Strategy, leading a global team and developing strategies for clinical studies.

Most recently, in 2022, Holger Koch joined HilleVax as the VP Analytical Research & Development.

Holger Koch completed their Vordiplom in Biology from Justus Liebig University Giessen from 1994 to 1996. Holger then pursued a Diplom in Cell and Molecular Biology, Pharmacology from Heidelberg University between 1996 and 1999. Afterward, they joined the University of Zurich and obtained their PhD in Biochemistry from 1999 to 2004. Finally, they completed a Postdoc in Antibody Selection and Characterization at the University of Zurich from 2004 to 2005.